Bristol-Myers Squibb (BMY), racing to convince shareholders to back its planned $74 billion acquisition of Celgene (CELG), could have its plans derailed by a pair of hugely influential financial advisers.
ISS and Glass Lewis, two global firms that make recommendations to institutional investors, are yet to weigh in on the potential merger. Together they claim a roughly 97 percent share of market for shareholder advice, and their verdict on the deal could spoil the largest pharmaceutical acquisition in history.
About the Author Reprints
